Joshua Hixson, MD
Family Medicine · Smyrna, TNNPI 1326056839
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 1,089 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,089 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Amgen$1K
- AbbVie$1K
- Pfizer$980
- Boehringer Ingelheim$940
- plus $9K from 54 others
What the payments were for
- Speaking & faculty fees$600%
- Food & beverage$17,57799%
- Education$560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,693 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 139 | $124,399 |
| XareltoRivaroxaban | 92 | $96,649 |
| OzempicSemaglutide | 42 | $94,384 |
| MounjaroTirzepatide | 73 | $91,713 |
| FarxigaDapagliflozin Propanediol | 68 | $74,690 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $62,872 |
| EliquisApixaban | 43 | $49,719 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 38 | $36,400 |
| ProliaDenosumab | 20 | $34,447 |
| MyrbetriqMirabegron | 29 | $32,754 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $31,692 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $26,428 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $26,369 |
| Repatha SureclickEvolocumab | 28 | $23,069 |
| JanuviaSitagliptin Phosphate | 18 | $19,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $940 | $172,615193 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,744 | $101,05991 claims |
| Johnson & JohnsonXarelto | $430 | $96,64992 claims |
| Novo NordiskOzempic | $2,281 | $94,38442 claims |
| Lilly USA, LLCMounjaro | $887 | $91,71373 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $863 | $89,300103 claims |
| PfizerEliquis | $980 | $49,71943 claims |
| AmgenProlia | $1,380 | $34,44720 claims |
| Astellas Pharma US IncMyrbetriq | $350 | $32,75429 claims |
| MerckJanuvia, Janumet | $362 | $30,37434 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $549 | $18,09619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Smyrna
- Kirsten BunceSmyrna$14K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.